Innovatus Capital Partners

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company based in Palo Alto, California, dedicated to developing targeted therapies for rare and ultra-rare diseases. The company’s lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently undergoing Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection. Eiger's pipeline also includes Lambda, which is in Phase 2 trials and targets type III interferon receptors for HDV, as well as Lonafarnib for progeria and progeroid laminopathies. Additionally, the company is developing Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia and is also in Phase 2 for congenital hyperinsulinism. Eiger's focus is on addressing high unmet medical needs in serious diseases where no approved therapies currently exist.

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company based in Palo Alto, California, dedicated to developing targeted therapies for rare and ultra-rare diseases. The company’s lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently undergoing Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection. Eiger's pipeline also includes Lambda, which is in Phase 2 trials and targets type III interferon receptors for HDV, as well as Lonafarnib for progeria and progeroid laminopathies. Additionally, the company is developing Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia and is also in Phase 2 for congenital hyperinsulinism. Eiger's focus is on addressing high unmet medical needs in serious diseases where no approved therapies currently exist.

DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Apollo Endosurgery is a medical technology company specializing in the design, development, and commercialization of devices aimed at enhancing gastrointestinal therapeutic endoscopy. Founded in 2005 and headquartered in Austin, Texas, the company offers a range of products, including the OverStitch Endoscopic Suturing System and the Orbera intragastric balloon system. These devices enable physicians to perform advanced endoscopic procedures, such as placing full-thickness sutures and reducing stomach capacity to aid in weight loss. Additionally, Apollo provides aftercare support through the Orbera Coach program. The company's products are utilized by gastroenterologists and bariatric surgeons across the United States, Brazil, Australia, and various European countries, addressing conditions like gastrointestinal perforations, chronic fistulas, and abnormal lesions. Apollo Endosurgery's innovations are rooted in collaboration with a network of leading gastroenterologists and surgeons who have sought to advance the field of therapeutic flexible endoscopy since 1998.

Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.

Geneoscopy, LLC is a diagnostic company based in Saint Louis, Missouri, focused on developing non-invasive solutions for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, Geneoscopy utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel aimed at identifying colorectal cancer by detecting the effects of cancer-related DNA mutations. The company is committed to improving colorectal cancer screening compliance and facilitating early detection, thereby reducing the associated morbidity and mortality. By employing a novel methodology to extract human RNA transcripts from stool samples, Geneoscopy aims to provide a reliable alternative to traditional colonoscopies, which are often viewed as unpleasant and invasive. In addition to its colorectal cancer diagnostic test, Geneoscopy is also exploring other potential applications of its RNA technology for additional gastrointestinal conditions.

Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.

Spacial is a San Francisco based company building accessory dwelling units for homeowner's backyards. The ADUs are beautiful, spacious and airy, and we utilize offsite construction increase speed to installation and decrease costs to homeowners, while delivering a home built to the same standard as their primary residence.

Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.

Match Marketing Group Inc. is a shopper marketing agency based in Mississauga, Canada, established in 2011. The company specializes in providing a comprehensive range of marketing solutions, including insights and strategy, digital and merchandising services, as well as activation and experiential marketing. They aim to inspire consumer purchases through seamless experiences that connect online and offline interactions. The agency's diverse clientele includes well-known brands such as adidas, GoGo Squeez, Malibu Rum, Lincoln Motor Company, and Ford. By focusing on the behaviors and preferences of connected shoppers, Match Marketing Group strives to enhance brand value and drive demand for its clients.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

VSA Partners, Inc. is a branding and marketing services firm that provides a range of solutions including strategy, digital systems, design, and marketing. Founded in 1982 and originally known as Vogele Stoik Associates, Inc., the company rebranded in December 1984. Headquartered in Chicago, Illinois, VSA Partners also has offices in New York and San Francisco. The firm caters to clients globally, offering services such as visual identity, corporate communication, retail design, and packaging. These services are designed to enhance digital interactions, allowing audiences to engage, share, and purchase effectively.

Akoya Biosciences is a spatial biology company offering the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.

Conformis, Inc. is a medical technology company based in Billerica, Massachusetts, specializing in the development, manufacturing, and sale of personalized joint replacement implants and instruments. Utilizing its proprietary iFit® Image-to-Implant® technology platform, Conformis creates individually sized and shaped implants tailored to fit each patient's unique anatomy. The company's product offerings include various knee replacement systems, such as iTotal CR, iTotal PS, iDuo, and iUni, as well as the Conformis Hip System and customized single-use instrumentation known as iJigs. Conformis markets its products primarily to hospitals and ambulatory surgical centers through a combination of its sales force, independent representatives, and distributors in multiple countries, including the United States and several European and Asian markets. The company emphasizes superior clinical outcomes and patient satisfaction compared to traditional off-the-shelf implants.

DNAnexus, Inc. specializes in cloud-based genome informatics and data management tools tailored for enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company provides a platform that facilitates the analysis of raw sequencing data, integrates genomic data with clinical information, and enhances collaboration among researchers. Key offerings include the MOSAIC Microbiome platform for microbiome research, DNAnexus Apollo for clinico-genomic data exploration, DNAnexus Titan for data analysis, and DNAnexus Portals, which create secure online workspaces for collaborative projects. Additionally, the Clinico-Genomic Data Solution aims to enhance disease-specific datasets through partnerships with healthcare providers, improving screening and treatment pathways for complex diseases. DNAnexus serves a diverse clientele, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Exagen is a life science company based in Vista, California, focused on the accurate diagnosis and monitoring of patients with autoimmune rheumatic diseases. Established in 2002, Exagen offers a range of testing products under its AVISE brand, which are designed to furnish objective information for physicians and patients. These tests facilitate accurate and timely diagnoses, enabling better management of autoimmune rheumatic diseases. Exagen primarily markets its solutions to community rheumatologists, addressing a significant unmet need in the field of rheumatology.